Study on Safety and Cost Calculation of DPP-IV inhibitor Use in Type 2 Diabetic Patients
Not Applicable
- Conditions
- Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
- Registration Number
- CTRI/2022/01/039294
- Lead Sponsor
- Dr TMA PAI FELLOWSHIP MAHE MANIPA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All type 2 diabetic patients aged between 40- 85 years on antidiabetic agents within the past six months of study initiation.
Exclusion Criteria
Type 1 diabetes mellitus, pregnancy, lactation, any malignancies, HIV infection, and patients on immunosuppressants
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cost-effectiveness analysis (CEA) and Cost-utility analysis (CUA) in type 2 diabetes patients who are on DPP-IV inhibitorsTimepoint: At baseline and followed every 6 months for 2.5 years with a minimum of 2 follow-up
- Secondary Outcome Measures
Name Time Method Diabetic complications such as hypoglycemia, nephropathy, neuropathy, and cardiovascular diseases <br/ ><br>Adverse drug reactions <br/ ><br>Number of readmissionsTimepoint: every 6 months followup along with baseline details